Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that the US Food and Drug Administration (FDA) has granted Priority Review to the nipocalimab Biologics License Application (BLA) for the treatment of antibody-positive generalised myasthenia gravis (gMG).
This decision is supported by positive results from the Phase 3 Vivacity-MG3 study, which demonstrated significant improvement in disease control with nipocalimab plus standard of care compared with placebo plus standard of care.
gMG is a rare autoimmune disease affecting approximately 700,000 people globally. Priority Review typically results in a shorter FDA review period, aiming to expedite the availability of potentially life-changing therapies.
J&J has also submitted a Marketing Authorisation Application for nipocalimab in gMG to the European Medicines Agency and received Breakthrough Therapy Designation from the FDA for the treatment of Sjögren's disease.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid